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for non-signal knee with OV as predictors (R2 > 0.09). Over 80% of the
correlations between DThCtAB and DOutcome examined had p-values
<0.05 at 1 and 3 Years, with most (13 of 22 at 1 Year and 12 of 20
at 3 Years) non-signiﬁcant correlations observed with Incidence cohort.
Correlation between DThCtAB at 1 Year and DOutcome at 3 Years was
signiﬁcant (p < 0.05) after adjusting for DOutcome at 1 Year for nearly all
outcomes.
Conclusions: DThCtAB at 1 year helps predict DOutcome at 3 Years even
after adjusting for DOutcome at 1 Year. The use of ordered values (OV)
as predictors produced larger R2 than use of subregion DThCtAB Results.
Non-signal knees of Progression cohort had larger R2 than signal knees.
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Purpose: There are several commercial enzyme-linked immunosorbent
assay (ELISA) kits available for measuring COMP levels in human serum;
however, these reagents lack speciﬁcity for degraded COMP fragments,
which may hinder the usefulness of the test for the clinical monitoring
of arthritis. The goal of this study is to develop a COMP fragment ELISA
to measure levels of proteolytic COMP fragments in serum, and to
determine whether detection of COMP degradative fragments will be
a more sensitive biomarker of arthritis.
Methods:We generated a panel of monoclonal antibodies (mAbs) against
COMP fragments and then characterized the mAbs domain speciﬁcity.
We developed a novel capture ELISA for detecting COMP fragments and
utilized this new test to measure the amount of degradative COMP
fragments in patients with osteoarthritis (OA) and rheumatoid arthritis
(RA). This test was also developed as an assay for the possible monitoring
of the effects of interventions. This new test was then used to monitor
OA progression in surgically induced OA animal models as well as the
alteration in COMP fragment levels in response to biological treatments
in collagen-induced arthritis (CIA) and TNF transgenic animal models.
Results: A panel of murine mAbs against recombinant COMP fragments
was generated and one of these clones, 2127F 5B6, was identiﬁed
as a mAb preferentially recognizing the COMP C-terminal degradative
fragments. A novel COMP fragment ELISA was then developed using
mAb 2127F 5 as a detection antibody. Compared with a commercial
COMP ELISA kit that detected no signiﬁcant difference in total COMP
levels between symptomatic knee OA (SKOA) and non-OA control groups,
a signiﬁcant increase of the COMP fragments was noted in the serum
of SKOA patients assayed by this newly established COMP ELISA. In
addition, serum COMP fragment levels were well correlated with the
Kellgren-Lawrence grade score in OA patients and the progression of
surgically induced OA in murine models. Furthermore, the levels of COMP
fragments in the serum of RA patients, mice with CIA, and TNF transgenic
mice were signiﬁcantly higher when compared with their corresponding
controls. Interestingly, treatments with TNFa inhibitors and methotrexate
led to a signiﬁcant decrease of serum COMP fragments in RA patients.
Additionally, administration of Atsttrin, a progranulin-derived engineered
protein that binds to TNFR and has potent anti-inﬂammatory activity
(Tang, et al, Science, 2011 Apr 22; 332(6028):478–484), also resulted in a
signiﬁcant reduction in serum COMP fragments in several inﬂammatory
arthritis mice models.
Conclusions: Using recombinant COMP fragments we have generated a
series of mAbs that recognize different domains on the COMP protein.
One of these antibodies that bind to the C-terminal portion of the
molecule was then used to develop a novel sandwich ELISA capable of
reproducibly measuring the levels of COMP fragments (COMP catabolism)
in the body ﬂuids of both arthritic patients and murine arthritis models.
In addition, this new test provides a valuable means to utilize serum
COMP fragments as a biomarker for monitoring the effects of therapeutic
interventions on arthritis.
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Purpose: Osteoarthritis (OA) is currently regarded as a complex joint
disease; multiple articular and peri-articular structures being involved,
probably in a variable sequence and dominance between individuals.
However, current literature on biochemical OA markers mainly concerns
small-scale assessments of limited numbers of biochemical markers and
is thereby discordant with this view. Instead, large-scale assessment
of multiple biochemical markers is preferable. Large-scale assessment
might be regarded unfeasible because of complex logistics, high ﬁnancial
burden, and the increased risk of inducing technical variability. This
publication analyzes the feasibility of such a large-scale assessment of a
wide spectrum of biochemical markers.
Methods: Eleven biochemical markers (CTX-II, COMP, CS846, PIIANP, C1,2C,
CTX-I, NTX-I, OC, PINP, PIIINP, HA) were assessed in urine or serum
samples of 1002 participants (Cohort Hip & Cohort Knee; CHECK) by
means of ELISA and RIA in an academic laboratory and commercially-
independent setting. The assessment was necessarily performed by
multiple technicians, in multiple assay plates, and during multiple
days. Therefore, speciﬁc attention to minimizing technically-induced
variability was vital. In addition to evaluation of several technical aspects,
reliability of single instead of multiple assessments per sample was
evaluated. A standard sample was repeatedly included in all assay
plates throughout the assessment period to quantify technically-induced
variability (3 levels: within plates, within all plates on a day, in all
plates throughout the assessment period) and evaluate adjustment for
between-plate variability.
Results: The additional variation that was introduced by single instead of
multiple sample assessments was limited and considered acceptable in the
context of logistics, scarcity of samples, and costs (triplicate assessment
in a subset of samples showed high correlation between biochemical
marker concentrations in the ﬁrst sample and the mean concentration
in triplets; rs 0.841–0.996, P 0.000). Of the 11,000 assessments that
were performed, 27 and 19 assessments showed concentrations that
were below or above the standard curve, respectively. Re-assessment in
adjusted dilutions induced (unpredictable) non-linear dilution effects
and was considered inappropriate. Instead, artiﬁcial concentrations
(0.8*minimum, 1.2*maximum concentration) were used. Technically-
induced variability increased stepwise between the 3 levels (intra-plate <
within day < total), but not statistically signiﬁcantly. Correction for
technically-induced between-plate variability on the basis of the standard
sample assessment that was performed in all plates decreased the CV% of
median biochemical marker concentrations between plates (mean ratio
after/before adjustment 0.96; SD 0.3). Three of the 11 biomarkers showed
unanticipated results. One could be re-assessed successfully, the other 2
remained unsolved, despite thorough analyses in consultancy with the
manufacturer.
Conclusions: Large-scale biochemical marker assessments pose speciﬁc
challenges. However, this study shows that large-scale assessment is
feasible for the vast majority of the studied biochemical markers.
This study was funded by CHECK (Cohort Hip & Cohort Knee), an initiative
of the Dutch Arthritis Association.
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Purpose: To determine if an association exists between circulating
concentrations of serum cartilage oligomeric matrix protein (COMP)
and fatty acids, and degree of osteoarthritic degradation of the medial
and lateral condyles of the tibial plateau graded according to the
Outerbridge Classiﬁcation, in patients undergoing total knee replacement
(TKR) surgery. Identiﬁcation of an easily accessible biomarker can aid in
determination of progressive osteoarthritis and in drug development.
Methods: Sera was collected from 113 individuals presenting for TKR,
representing both male (n =51) and female (n = 62) patients with an
